Skip to Main content Skip to Navigation
Journal articles

The immuno-oncological challenge of COVID-19

Abstract : Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19. Zitvogel and colleagues discuss the interplay between cancer and COVID-19 with respect to patient risk and prognosis, immune responses and potential therapies.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03149699
Contributor : Isabelle Combe <>
Submitted on : Tuesday, February 23, 2021 - 11:52:43 AM
Last modification on : Thursday, April 15, 2021 - 3:08:11 PM

Links full text

Identifiers

Citation

Lisa Derosa, Clea Melenotte, Franck Griscelli, Bertrand Gachot, Aurelien Marabelle, et al.. The immuno-oncological challenge of COVID-19. NATURE CANCER, 2020, 1 (10), pp.946-964. ⟨10.1038/s43018-020-00122-3⟩. ⟨hal-03149699⟩

Share

Metrics

Record views

22